Docoh
Loading...

53 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute … , of the Commission and the FINRA Corporate Financing Department (including, with respect to any required review by FINRA, the reasonable fees and expenses
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any … , offer, pay, promise to pay or authorize the giving of money or anything of value to any official or employee of any government or any department
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
in the United States in addition to the FDA, including Centers for Medicare and Medicaid Services (CMS), other divisions of the Department of Health … and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
of Foreign Assets Control of the U.S. Treasury Department (“OFAC”). (nn) U.S. Real Property Holding Corporation. The Company is not and has never been
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
that is: (1) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control, the United
424B4
nkh5an97ok5fsm18
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
i20b h1b3bc12cw
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
6w9d0ln
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
rgxb2
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.13
hilu89i dhnm
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.1
trjblx lor
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.11
g5czy94joq1fwtk4bine
16 Sep 20
IPO registration (amended)
8:00pm
8-K
EX-10.1
a4wgmkcbp0vn2qa
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
ly1pnop5r1zzmgry x6
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
S-1/A
65dom38febw6lra ph
17 Jul 20
IPO registration (amended)
5:25pm
10-K
lnetw
5 Mar 20
Annual report
7:00pm
S-1
5cg n83vx3vuvm3coc4
13 Dec 19
IPO registration
5:32pm
10-K/A
aososilyq h5j2a
5 Apr 19
Annual report (amended)
9:40pm
10-K
454vo 4aipk1hbrauj
28 Mar 19
Annual report
5:25pm
424B3
sosdja keqxzbct726x
13 Nov 18
Prospectus supplement
9:39pm